About
Technology
Issues
FAQ
Links
Official Page
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.